A practical approach to immune monitoring in kidney transplantation

Minerva Urologica e Nefrologica

Volumn 59, Issue 3, 2007, Pages 337-352

  Rodrigo, E ^a,b   Arias, M ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Graft rejection; Immune tolerance; Infections; Kidney transplantation; Monitoring, immunologic

Indexed keywords

CALCINEURIN INHIBITOR; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD30 ANTIGEN; CYCLOSPORIN; FINGOLIMOD; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ANTIGEN DETECTION; CELL PROLIFERATION; DENDRITIC CELL; DRUG MECHANISM; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY;

DENDRITIC CELLS; GENE EXPRESSION; HUMANS; KIDNEY TRANSPLANTATION; MONITORING, IMMUNOLOGIC; PHENOTYPE; T-LYMPHOCYTES;

EID: 36749019102     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Soulillou J. Immune monitoring for rejection of kidney transplants. New Engl J Med 2001;344:1006-7.
2. Mannon RB, Kirk AD. Beyond histology: novel tools to diagnose allograft dysfunction. Clin J Am Soc Nephrol 2006;1:358-66.
3. Zand MS. Immunosuppression and immune monitoring after renal transplantation. Semin Dial 2005;18:511-9.
4. Newell KA, Larsen CP. Tolerance assays: measuring the unknown. Transplantation 2006;81:1503-9.
5. Heeger PS, Hricik D. Immune monitoring in kidney transplant recipients revisited. J Am Soc Nephrol 2002;13:288-90.
6. Reding R, Gras J, Truong DQ, Wieërs G, Latinne D. The immunological monitoring of alloreactive responses in liver transplant recipients: a review. Liver Transpl 2006;12:373-83.
7. Lau AH, Turnquist HR, Tokita D, Zeevi A, Mazariegos GV, Thomson AW. "Tolerance" assays: the physician's guide to safe weaning of immunosuppression? Transplant Rev 2006;20:208-21.
8. Süsal C, Pelzl S, Simon T, Opelz G. Advances in pre-and posttransplant immunologic testing in kidney transplantation. Transplant Proc 2004;36:29-34.
9. Najafian N, Albin MJ, Newell KA. How can we measure immunologic tolerance in humans? J Am Soc Nephrol 2006;17:2652-63.
10. Martinez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, Rimola A et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007;7:309-19.
11. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000;11: 1910-7.
12. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001;344:655-64.
13. Hariharan S. Recommendations for outpatient monitoring of kidney transplant recipients. Am J Kidney Dis 2006;47 Suppl 2:22-36.
14. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005;16:3015-26.
15. Perico N, Ruggenenti P, Gotti E, Gaspari F, Cattaneo D, Valente U et al. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial. Kidney Int 2004;65:1084-90.
16. Sommerer C, Konstandin M, Dengler T, Schmidt J, Meuer S, Zeier M et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006;82:1280-5.
17. Borrows R, Chusney G, Loucaidou M, James A, Lee J, Tromp JV et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006;6:121-8.
18. Rodrigo E, Piñera C, de Cos MA, Sánchez B, Ruiz JC, Fernández-Fresnedo G et al. New onset diabetes mellitus risk factors after kidney transplantation: higher initial tacrolimus blood levels and concentration-dose ratios. Transplant Int 2005;18:1152-7.
19. Weimar W, Rischen-Vos J, de Kuiper P, Gregoor PJ, Ijzermans JN, van Besouw NM et al. Tapering immunosuppression in recipients of living donor kidney transplants. Nephrol Dial Transplant 2004;19 Suppl 4:61-3.
20. Zand MS, Bose A, Vo T, Coppage M, Pellegrin T, Arend L et al. A renewable source of conor cells for repetitive monitoring of T- and B-cell alloreactivity. Am J Transplant 2005;5:76-86.
21. van Besouw NM, Zuijderwijk JM, de Kuiper P, Ijzermans JNM, Weimar W, van der Mast BJ. The granzyme B and interferon-γ enzyme-linked immunospot assay as alternatives for cytotoxin T-Lymphocyte precursor frequency after renal transplantation. Transplantation 2005;79:1062-6.
22. Augustine JJ, Siu DS, Clemente MJ, Schulak JA, Heeger PS, Hricik DE. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005;5:1971-5.
23. Nickel P, Presber F, Bold G, Biti D, Schonemann C, Tullius SG et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004;78:1640-6.
24. Augustine JJ, Poggio ED, Clemente MJ, Aeder MI, Schulak JA, Heeger PS et al. Towards individualized treatment of kidney transplant recipients: pretransplant anti donor cellular immunity by IFN-γ ELISPOT identifies candidates that can most benefit from induction therapy. Am J Transplant 2006;6 Suppl 2:649.
25. Bellisola G, Tridente G, Nacchia F, Fior F, Boschiero L. Monitoring of cellular immunity by interferon-gamma enzyme-linked immunosorbent spot assay in kidney allograft recipients: preliminary results of a longitudinal study. Transplant Proc 2006;38:1014-7.
26. van den Boogaardt DE, van Miert PP, de Vaal YJ, de Fijter JW, Claas FH, Roelen DL. The ratio of interferon-gamma and interleukin-10 producing donor-specific cells as an in vitro monitoring tool for renal transplant patients. Transplantation 2006;82:844-8.
27. Lindemann M, Witzke O, Lutkes P, Fiedler M, Kreuzfelder E, Philipp T et al. ELISPOT assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients. Clin Immunol 2006;120:342-8.
28. Jankowska-Gan E, Sollinger HW, Pirsch JD, Radke N, Lillesand C, Janus C et al. Delayed-type hypersensitivity (DTH) assay correlates with outcome of steroid withdrawal in older transplant recipients. Am J Transplant 2006;6 Suppl 2:582.
29. Zachary AA, Kopchaliiska D, Montgomery RA, Melancon JK, Leffell MS. Predicting post-transplant de novo production of HLA-specific antibody. Am J Transplant 2006;6 Suppl 2:242.
30. Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006;81:81-7.
31. Fernández-Fresnedo G, Pastor JM, López-Hoyos M, Ruiz JC, Zubimendi JA, González-Cotorruelo J et al. Relationship of donor-specific class-I anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival. Nephrol Dial Transplant 2003;18:990-5.
32. Worthington JE, Martín S, Al-Husseini DM, Dyer PA, Jonson RWG. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003;75:1034-40.
33. Campos EF, Tedesco-Silva H, Machado PG, Franco M, Medina-Pestana JO, Gerbase-DeLima M. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006;6:2316-20.
34. Lefaucheur C, Nochy D, Hill GS, Suberbielle-Boissel C, Antoine C, Charron D et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007;7:832-41.
35. Worthington JE, McEwen A, McWilliam LJ, Picton ML, Martin S. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007;83:398-403.
36. Regele H, Bohmig GA, Habicht A, Gollowitzer D, Schillinger M, Rockenschaub S et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002;13:2371-80.
37. Langan LL, Park LP, Hughes TL, Irish A, Luxton G, Witt CS et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007;7:847-56.
38. Mao Q, Terasaki PI, Cai J, Briley K, Catrou P, Haisch C et al. Extremely high assciation between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007;7:864-71.
39. Scornik JC, Schold JD, Guerra G, Srinivas TR, Meier-Kriesche H-U. HLA antibody testing for the management of kidney graft dysfunction. Am J Transplant 2006;6 Suppl 2:638.
40. Mizutani K, Terasaki P, Hamdani E, Esquenazi V, Rosen A, Miller J et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007;7:1027-31.
41. Mazariegos GV, Zahorchak AF, Reyes J, Chapman H, Zeevi A, Thomson A. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 2005;5:314-22.
42. Vaidya S, Partlow D, Barnes T, Thomas P, Gugliuzza K. Soluble CD30 concentration in ESRD patients with and without panel reactive HLA antibodies. Clin Transplant 2006;20:461-4.
43. Garcia LF, Rodríguez LM, París SC, Cotes JM, Torres Y, Süsal C. Effect of anti-HLA class I and II sCD30 and IgA anti-FAB on cadaveric kidney graft survival. A single center experience. Am J Transplant 2006:6 Suppl 2:776.
44. Pelzl S, Opelz G, Daniel V, Wiesel M, Süsal C. Evaluation of posttransplantation soluble cd30 for diagnosis of acute renal allograft rejection. Transplantation 2003;75:421-3.
45. Matinlauri IH, Kyllönen LEJ, Salmela KT, Helin H, Pelzl S, Süsal C. Serum CD30 in monitoring of alloresponse in web HLA-matched cadaveric kidney transplantations. Transplantation 2005;80:1809-12.
46. Sengul S, Keven K, Gormez U, Kutlay S, Erturk S, Erbay B. identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation 2006;81:1216-9.
47. Weimer R, Süsal C, Yildiz S, Staak A, Pelzl S, Renner F et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 2006;6: 1865-74.
48. Creput C, Le Friec G, Bahri R, Amiot L, Charpentier B, Carosella E et al. Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol 2003;64:1033-8.
49. Le Rond S, Azema C, Krawice-Radanne I, Durrbach A, Guettier C, Carosella ED et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells. J Immunol 2006;176:3266-76.
50. Creput C, Durrbach A, Menier C, Guettier C, Samuel D, Dausset J et al. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 2003;39:587-94.
51. Qiu J, Terasaki PI, Miller J, Mizutani K, Cai J, Carosella ED. Soluble HLA-G expresión and renal graft acceptance. Am J Transplant 2006;6:2152-6.
52. + T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006;81:398-407.
53. Dadhania D, Snopkowski C, Muthukumar T, Lee J, Ding R, Li B et al. A biologic mechanism for the failure of allografts over time: loss of FOXP3 expressing T regulatory cells and ascendancy of granzyme B expressing cytopathic cells. Am J Transplant 2006;6 Suppl 2:699.
54. + T regulatory cells (TREGS) in human kidney allograft biopsies: phenotype and relation to rejection type, tubulitis and outcome. Am J Transplant 2006;6 Suppl 2: 410.
55. Belingheri M, Gross DM, Edefonti A, Bluestone JA, Vincenti F. Ratio of regulatory T cells to Cd3 infiltrate predicts renal allograft outcome after acute cellular rejection. Am J Transplant 2006;6 Suppl 2:635.
56. Ciubotariu R, Vasilescu R, Ho E, Cinti P, Cancedda C, Poli L et al. Detection of T supresor cells in patients with organ allografts. Hum Immunol 2001;62:15-20.
57. Cortesini R, Renna-Molajoni E, Cinti P, Pretagostini R, Ho E, Rossi P et al. Tailoring of immunosuppression in renal and liver allograft recipients displaying donor-specific T-supressor cells. Hum Immunol 2002;63:1010-8.
58. + regulatory T cells. Blood 2006;107:1018-23.
59. Game DS, Hernandez-Fuentes MP, Lechler RI. Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am J Transplant 2005;5:454-64.
60. + FOXP3 regulatory T cells in renal transplant recipients. Transplantation 2006;82:550-7.
61. Gasser M, Tsaur I, Aviles B, Lopau K, Lebedeva T, Trumpfheller A et al. Analysis of allospecific T cells in kidney transplant patients on various immunosuppressive protocols. Am J Transplant 2006;6 Suppl 2:692.
62. + regulatory T cells. J Am Soc Nephrol 2006;17:2844-53.
63. Gross DM, Belingheri M, Vincenti F, Bluestone JA. Enhanced regulatory T cell infiltration of renal allografts in the presence of costimulation blockade with belatacept. Am J Transplant 2006;6 Suppl 2:375.
64. Wakkach A, Fournier N, Brun V, Breitmayer J, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003;18:605-17.
65. Abe M, Wang Z, de Creus A, Thomson AW. Plasmacytoid dendritic cell precursors induce allogeneic T-cell hyporesponsiveness and prolong heart graft survival. Am J Transplant 2005;5:1808-19.
66. Mazariegos GV, Zahorchak AF, Reyes J, Ostrowski L, Flynn B, Zeevi A et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 2003;3:689-96.
67. Hesselink DA, Vaessen LM, Hop WC, Schoordijk W, Ijzermans JN, Baan CC et al. The effects of renal transplantation on circulating dendritic cells. Clin Exp Immunol 2005;140:384-93.
68. Womer KL, Peng R, Patton PR, Murawski MR, Bucci M, Kaleem A et al. The effects of renal transplantation on peripheral blood dendritic cells. Clin Transplant 2005;19:659-67.
69. Hackstein H, Renner FC, Bohnert A, Nockher A, Frommer T, Bein G et al. Dendritic cell deficiency in the blood of kidney transplant patients on long-term immunosuppression: results of a prospective matched-cohort study. Am J Transplant 2005;5:2945-53.
70. Lim WH, Kireta S, Thomson AW, Russ GR, Coates PT. Renal transplantation reverses functional deficiencies in circulating dendritic cell subsets in chronic renal failure patients. Transplantation 2006;81:160-8.
71. Rondelli D, Abbasian J, Arpinati M, Panaro F, Porubsky M, Manzelli A et al. Different reconstitution of peripheral blood lymphocytes and dendritic cells in liver and kidney transplant patients. Transplant Proc 2005;37:49-50.
72. Kirsch BM, Haidinger M, Zeyda M, Bohmig GA, Tombinsky J, Muhlbacher F, et al. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol 2006;16:254-7.
73. Alvarez CM, Opelz G, Giraldo MC, Pelzl S, Renner F, Weimer R et al. Evaluation of T-cell receptor repertoires in patients with long-term renal allograft siurvival. Am J Transplant 2005;5:746-56.
74. Brouard S, Dupont A, Giral M, Louis S, Lair D, Braudeau C et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005;5:330-40.
75. Miqueu P, Guillet M, Doré J-C, Soulillou J-P, Brouard S. Discrimination of kidney transplant recipients presenting operational tolerance or chronic rejection based on recognition of T cell receptor CD3 length distribution patterns. Am J Transplant 2006;6 Suppl 2:403.
76. Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006;82:663-8.
77. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M et al. Immune cell function testing: an adjunct to therapeutic drug mintoring in transplant patient management. Clin Transplant 2003;17:77-88.
78. Cadillo-Chávez R, de Echegaray S, Santiago-Delpín EA, Rodríguez-Trinidad AT, Camacho-Carrazo B, Alfaro T et al. Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transplant Proc 2006;38:918-29.
79. Zeevi A, Britz JA, Bentlejewski CA, Guaspari D, Tong W, Bond G et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 2005;15:17-24.
80. Valero R, Sanchez-Velasco P, Rodrigo E, Ruiz JC, Leyva F, Arias M. Assessment about risk of infection in kidney transplant by measuring the concentration of ATP from CD4 cells following stimulation by CYLEX. Am J Transplant 2006;6 Suppl 2:486.
81. Thai NL, Blisard D, Tom K, Basu A, Smetkana C, Tan H et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: correlation between low T-cell responses and infection. Transplantation 2006;82:1649-52.
82. Hotchkiss H, Chu TT, Hancock WW, Schroppel B, Kretzler M, Schmid H et al. Differential expression of profibrotic and growth factors in chronic allograft nephropathy. Transplantation 2006;81:342-9.
83. Scherer A, Krause A, Walker JR, Korn A, Niese D, Raulf F. Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation 2003;75:1323-30.
84. Flechner SM, Kurian SM, Head SR, Sharp SM, Whisenant TC, Zhang J et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004;4:1475-89.
85. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003;349:125-38.
86. Weintraub LA, Sarwal MM. Microarrays: a monitoring tool for transplant patients. Transplant Int 2006;19:775-88.
87. Alakulppi NS, Kyllönen LE, Partanen J, Salmela KT, Laine JT. Diagnosis of acute renal allograft rejection by analyzing whole blood mRNA expression of lymphocyte marker molecules. Transplantation 2007;83: 791-8.
88. Mas VR, Maluf DG, Archer KJ, Yanek K, King A, Cotterell A et al. Study of mRNA growth factors in urinary cells of kidney transplant recipients as predictors of chronic allograft nephropathy. Transplantation 2005;80:1686-91.
89. Li B, Hartono C, Ding R, Sharma VK, Ramaswamy R, Qian B et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger rna for perforin and granzyme b in urine. N Engl J Med 2001;13:947-54.
90. Yannaraki M, Rebibou JM, Ducloux D, Saas P, Duperrier A, Felix S et al. Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection. Transpl Int 2006;19:759-68.
91. Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005;353:2342-51.
92. Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS, Molmenti EP. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 2003;237:660-4.
93. O'Riordan E, Orlova TN, Mei JJ, Butt K, Chander PM, Rahman S et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 2004;15:3240-8.
94. Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004;15:219-27.
95. Wittke S, Haubitz M, Walden M, Rohde F, Schwarz A, Mengel M et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant 2005;5:2479-88.
96. Jahnukainen T, Malehorn D, Sun M, Lyons-Weiler J, Bigbee W, Gupta G et al. Proteomic analysis of urine in kidney transplant patients with BK virus nephropathy. J Am Soc Nephrol 2006;17:3248-56.